Our Company
Presentation
Presentation post-ASCO
Half-year results 2022
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
OSE-127
FR104
BI 765063
OSE-230
CLEC-1
BiCKI®
Research & Development
Scientific publications
Investors
Press Releases
Regulated information
Financial documents
General Shareholders’ meetings
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
Retour aux communiqués
Date
Servier and OSE Immunotherapeutics announce completion of patient enrollment in the Phase 2a clinical trial of OSE-127/S95011 in primary Sjögren’s syndrome
Téléchargez